Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has announcements × CP protocol × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

Carboplatin 32 Cisplatin 27 pembrolizumab 25 Paclitaxel 25 Pemetrexed 20 Nivolumab 18 Gemcitabine 18 Dexamethasone 15 Rituximab 14 Ipilimumab 12 Fluorouracil 11 Docetaxel 11 durvalumab 10 Cyclophosphamide 10 Lenalidomide 9 Bevacizumab 9 olaparib 8 atezolizumab 8 Cytarabine 8 Capecitabine 8 130-nm albumin-bound paclitaxel 8 daratumumab 7 Prednisone 7 Leucovorin 7 Etoposide 7 Doxorubicin 7 Bortezomib 7 venetoclax 6 osimertinib 6 Trastuzumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03737643 2025-01-29

DUO-O

AstraZeneca

Phase 3 Active not recruiting

1,407 enrolled 2 FDA

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡